230 related articles for article (PubMed ID: 25884688)
1. Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis.
Blaschke S; Rinke K; Maring M; Flad T; Patschan S; Jahn O; Mueller CA; Mueller GA; Dihazi H
Arthritis Res Ther; 2015 Mar; 17(1):45. PubMed ID: 25884688
[TBL] [Abstract][Full Text] [Related]
2. High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients.
Tan W; Wang F; Guo D; Ke Y; Shen Y; Lv C; Zhang M
Int J Rheum Dis; 2016 May; 19(5):482-9. PubMed ID: 24863583
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study.
Jamnitski A; Visman IM; Peters MJ; Dijkmans BA; Voskuyl AE; Nurmohamed MT
Ann Rheum Dis; 2010 Nov; 69(11):1929-33. PubMed ID: 20498216
[TBL] [Abstract][Full Text] [Related]
4. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.
Castro-Villegas C; Pérez-Sánchez C; Escudero A; Filipescu I; Verdu M; Ruiz-Limón P; Aguirre MA; Jiménez-Gomez Y; Font P; Rodriguez-Ariza A; Peinado JR; Collantes-Estévez E; González-Conejero R; Martinez C; Barbarroja N; López-Pedrera C
Arthritis Res Ther; 2015 Mar; 17(1):49. PubMed ID: 25860297
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
6. ¹H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis.
Priori R; Casadei L; Valerio M; Scrivo R; Valesini G; Manetti C
PLoS One; 2015; 10(11):e0138537. PubMed ID: 26558759
[TBL] [Abstract][Full Text] [Related]
7. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
9. Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer.
Chen CB; Su YC; Huang TT; Ho HC; Chang YT; Tung YT; Lee WC
Clin Chim Acta; 2008 Dec; 398(1-2):48-52. PubMed ID: 18727923
[TBL] [Abstract][Full Text] [Related]
10. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
[TBL] [Abstract][Full Text] [Related]
11. Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach.
Obry A; Lequerré T; Hardouin J; Boyer O; Fardellone P; Philippe P; Le Loët X; Cosette P; Vittecoq O
PLoS One; 2014; 9(12):e115800. PubMed ID: 25546405
[TBL] [Abstract][Full Text] [Related]
12. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
[TBL] [Abstract][Full Text] [Related]
14. Etanercept Immunex.
Yung RL
Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
16. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.
Jamnitski A; Krieckaert CL; Nurmohamed MT; Hart MH; Dijkmans BA; Aarden L; Voskuyl AE; Wolbink GJ
Ann Rheum Dis; 2012 Jan; 71(1):88-91. PubMed ID: 21914626
[TBL] [Abstract][Full Text] [Related]
17. Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use.
Lim MJ; Kwon SR; Joo K; Son MJ; Park SG; Park W
Korean J Intern Med; 2014 Nov; 29(6):807-13. PubMed ID: 25378980
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
[TBL] [Abstract][Full Text] [Related]
19. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
[TBL] [Abstract][Full Text] [Related]
20. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis.
Nguyen MVC; Baillet A; Romand X; Trocmé C; Courtier A; Marotte H; Thomas T; Soubrier M; Miossec P; Tébib J; Grange L; Toussaint B; Lequerré T; Vittecoq O; Gaudin P
Joint Bone Spine; 2019 Mar; 86(2):195-201. PubMed ID: 29885551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
